PRESCIENT THERAPEUTICS LIMITED - Announcements

Market Cap $32.21M Add to my watchlist

Healthcare Biotechnology

Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The... Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The Company is developing personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 has completed Phase Ib expansion cohort study in relapsed and refractory T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. OmniCAR is a universal immune receptor platform being developed to enable controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumors. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumor microenvironment.More

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

PTX	September 2018 Appendix 4C - Quarterly	PRICE SENSITIVE	31/10/18	164.4KB	Share
PTX	Pipeline Collaboration for Next Generation Formulations	PRICE SENSITIVE	17/10/18	246.34KB	Share
PTX	Canadian Patent Granted for PTX-200	PRICE SENSITIVE	24/09/18	240.28KB	Share
PTX	Improved manufacturing route for PTX-100	PRICE SENSITIVE	03/09/18	118.87KB	Share
PTX	Appendix 4E and 2018 Annual Report	PRICE SENSITIVE	31/08/18	1.73MB	Share
PTX	PTX-200 AML Study Expanded	PRICE SENSITIVE	30/08/18	246.28KB	Share
PTX	June 2018 Appendix 4C - Quarterly	PRICE SENSITIVE	31/07/18	439.86KB	Share
PTX	US Patent Granted for PTX-200 for Ovarian Cancer Treatment	PRICE SENSITIVE	26/07/18	384.4KB	Share
PTX	March 2018 Appendix 4C - Quarterly	PRICE SENSITIVE	23/04/18	439.63KB	Share
PTX	Response to Aware Query	PRICE SENSITIVE	12/04/18	682.86KB	Share
PTX	PTX-200 Phase 1b Breast Cancer Trial Results	PRICE SENSITIVE	10/04/18	153.25KB	Share
PTX	March 2018 Investor Presentation	PRICE SENSITIVE	19/03/18	2.64MB	Share
PTX	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	27/02/18	588.3KB	Share
PTX	Receipt of R&D Tax Rebate	PRICE SENSITIVE	01/02/18	96.13KB	Share
PTX	December 2017 Appendix 4C - Quarterly	PRICE SENSITIVE	31/01/18	214.8KB	Share
PTX	Clinical Trial Updates	PRICE SENSITIVE	29/01/18	108.02KB	Share
PTX	Clinical Hold Lifted on PTX-200 Breast Cancer Trial	PRICE SENSITIVE	11/12/17	189.03KB	Share
PTX	PTX to resume Clinical Trial of PTX-200 in Ovarian Cancer	PRICE SENSITIVE	06/11/17	190.6KB	Share
PTX	September 2017 Appendix 4C - Quarterly	PRICE SENSITIVE	27/10/17	420.15KB	Share
PTX	PTX-100 to Re-enter Trials in Hematology Niche	PRICE SENSITIVE	03/10/17	167.41KB	Share
PTX	Prescient to resume AML trial	PRICE SENSITIVE	04/09/17	234.23KB	Share
PTX	Appendix 4E and 2017 Annual Report	PRICE SENSITIVE	29/08/17	1.02MB	Share
PTX	June 2017 Appendix 4C - Quarterly	PRICE SENSITIVE	26/07/17	426.92KB	Share
PTX	Novel PTX-100 Cancer Approach Published in Nature	PRICE SENSITIVE	19/06/17	252.6KB	Share
PTX	Clinical Trial Update	PRICE SENSITIVE	29/05/17	99.59KB	Share
PTX	PTX Broker Presentation	PRICE SENSITIVE	16/05/17	2.62MB	Share
PTX	European Patent Granted for PTX-200	PRICE SENSITIVE	12/05/17	111.75KB	Share
PTX	Kansas University Joins PTX's AML Trial	PRICE SENSITIVE	08/05/17	297.41KB	Share
PTX	FDA Grants Orphan Drug Designation for PTX-200 in AML	PRICE SENSITIVE	01/05/17	137.25KB	Share
PTX	March 2017 Appendix 4C - Quarterly	PRICE SENSITIVE	27/04/17	139.83KB	Share
PTX	Successful Completion of Phase 1b Breast Cancer Trial	PRICE SENSITIVE	06/04/17	140.85KB	Share
PTX	Trading Halt	PRICE SENSITIVE	04/04/17	319.66KB	Share
PTX	Response to ASX Price Query	PRICE SENSITIVE	28/03/17	574.71KB	Share
PTX	Three Additional US Patents Granted	PRICE SENSITIVE	16/03/17	95.03KB	Share
PTX	First Cohort Successfully Completed in Phase 1b/2 AML Trial	PRICE SENSITIVE	08/03/17	193.1KB	Share
PTX	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	23/02/17	596.12KB	Share
PTX	December 2016 Appendix 4C - Quarterly	PRICE SENSITIVE	25/01/17	158.04KB	Share
PTX	First Patient Dosed on Phase 1b/2 AML Trial	PRICE SENSITIVE	14/12/16	111KB	Share
PTX	Phase 1b/2 Ovarian Trial Commences 2nd Dose Escalation	PRICE SENSITIVE	08/12/16	408.73KB	Share
PTX	Receipt of R&D Tax Rebate-PTX.AX	PRICE SENSITIVE	02/11/16	205.19KB	Share
PTX	September 2016 Appendix 4C - Quarterly-PTX.AX	PRICE SENSITIVE	28/10/16	395.63KB	Share
PTX	Response to ASX Price Query-PTX.AX	PRICE SENSITIVE	19/10/16	716.25KB	Share
PTX	First patient at Moffitt dosed in Phase 1b/2 breast trial-PTX.AX	PRICE SENSITIVE	26/09/16	225.64KB	Share
PTX	Appendix 4E and 2016 Annual Report-PTX.AX	PRICE SENSITIVE	31/08/16	800.39KB	Share
PTX	USPTO Grants Allowances for Two PTX-200 Patents-PTX.AX	PRICE SENSITIVE	04/08/16	269.27KB	Share
PTX	Change to exercise price of options-PTX.AX	PRICE SENSITIVE	20/07/16	218.84KB	Share
PTX	June 2016 Appendix 4C - Quarterly-PTX.AX	PRICE SENSITIVE	20/07/16	197.07KB	Share
PTX	Yale Joins PTX's Phase 1b/2 AML Clinical Trial-PTX.AX	PRICE SENSITIVE	15/06/16	269.24KB	Share
PTX	Replacement Entitlement Offer Prospectus-PTX.AX	PRICE SENSITIVE	03/06/16	1.14MB	Share
PTX	Offer Document-PTX.AX	PRICE SENSITIVE	18/05/16	4.24MB	Share
PTX	PTX Secures $7.0M Capital Raising-PTX.AX	PRICE SENSITIVE	18/05/16	137.01KB	Share
PTX	Trading Halt-PTX.AX	PRICE SENSITIVE	16/05/16	532KB	Share
PTX	March 2016 Appendix 4C - Quarterly-PTX.AX	PRICE SENSITIVE	21/04/16	391.12KB	Share
PTX	PTX-200 Breast Cancer Trial Progresses	PRICE SENSITIVE	17/02/16	128.83KB	Share
PTX	Steven Yatomi-Clarke Appointed CEO	PRICE SENSITIVE	15/02/16	265.75KB	Share
PTX	December 2015 Appendix 4C - Quarterly	PRICE SENSITIVE	25/01/16	467.39KB	Share
PTX	Response to ASX Price Query	PRICE SENSITIVE	19/01/16	671.55KB	Share
PTX	FDA Allows PTX IND for Leukemia Phase Ib & II Trials	PRICE SENSITIVE	08/01/16	332.21KB	Share
PTX	Additional Placement Raises $1.0 million	PRICE SENSITIVE	25/11/15	126.81KB	Share
PTX	September 2015 Appendix 4C - Quarterly	PRICE SENSITIVE	30/10/15	460.96KB	Share
PTX	SPP Fully Underwritten up to target amount of $1.03 million	PRICE SENSITIVE	29/10/15	278.96KB	Share
PTX	Trading Halt	PRICE SENSITIVE	28/10/15	554.76KB	Share
PTX	Executive Management Change	PRICE SENSITIVE	15/10/15	108.29KB	Share
PTX	Two new Patents granted to Protect Lead Asset PTX-200	PRICE SENSITIVE	31/08/15	143.62KB	Share
PTX	Prescient Appendix 4E and 2015 Annual Report	PRICE SENSITIVE	28/08/15	588.32KB	Share
PTX	PTX-200 Phase 1B/2 Clinical Trial Update	PRICE SENSITIVE	26/08/15	351.17KB	Share
PTX	Proposed Grant of Options to Non-Executive Directors	PRICE SENSITIVE	21/08/15	124.29KB	Share
PTX	June 2015 Appendix 4C - Quarterly	PRICE SENSITIVE	30/07/15	463.75KB	Share
PTX	IND for Phase 1b/2 Ovarian Cancer Trial Transferred to PTX	PRICE SENSITIVE	29/06/15	126.1KB	Share
PTX	US FDA Reactivates PTX's IND for PTX-100 Breast Cancer Trial	PRICE SENSITIVE	10/06/15	145.57KB	Share
PTX	March 2015 Appendix 4C - Quarterly	PRICE SENSITIVE	29/04/15	434.22KB	Share
PTX	Encouraging Pre-Clinical Data Presented at US Cancer Meeting	PRICE SENSITIVE	21/04/15	347.82KB	Share
PTX	Approval received to transfer IND Sponsorship for PTX-200	PRICE SENSITIVE	01/04/15	68.29KB	Share
PTX	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	27/02/15	1.02MB	Share
PTX	Prescient Therapeutics Granted Key U.S. Patents	PRICE SENSITIVE	23/02/15	210.04KB	Share
PTX	PTX Acquires Worldwide License for Cancer Biomarker p27	PRICE SENSITIVE	09/02/15	74.34KB	Share
PTX	December 2014 Appendix 4C - quarterly	PRICE SENSITIVE	30/01/15	322.22KB	Share

PTX September 2018 Appendix 4C - Quarterly
31/10/18	PRICE SENSITIVE	164.4KB	Share
PTX Pipeline Collaboration for Next Generation Formulations
17/10/18	PRICE SENSITIVE	246.34KB	Share
PTX Canadian Patent Granted for PTX-200
24/09/18	PRICE SENSITIVE	240.28KB	Share
PTX Improved manufacturing route for PTX-100
03/09/18	PRICE SENSITIVE	118.87KB	Share
PTX Appendix 4E and 2018 Annual Report
31/08/18	PRICE SENSITIVE	1.73MB	Share
PTX PTX-200 AML Study Expanded
30/08/18	PRICE SENSITIVE	246.28KB	Share
PTX June 2018 Appendix 4C - Quarterly
31/07/18	PRICE SENSITIVE	439.86KB	Share
PTX US Patent Granted for PTX-200 for Ovarian Cancer Treatment
26/07/18	PRICE SENSITIVE	384.4KB	Share
PTX March 2018 Appendix 4C - Quarterly
23/04/18	PRICE SENSITIVE	439.63KB	Share
PTX Response to Aware Query
12/04/18	PRICE SENSITIVE	682.86KB	Share
PTX PTX-200 Phase 1b Breast Cancer Trial Results
10/04/18	PRICE SENSITIVE	153.25KB	Share
PTX March 2018 Investor Presentation
19/03/18	PRICE SENSITIVE	2.64MB	Share
PTX Appendix 4D and Half Year Financial Report
27/02/18	PRICE SENSITIVE	588.3KB	Share
PTX Receipt of R&D Tax Rebate
01/02/18	PRICE SENSITIVE	96.13KB	Share
PTX December 2017 Appendix 4C - Quarterly
31/01/18	PRICE SENSITIVE	214.8KB	Share
PTX Clinical Trial Updates
29/01/18	PRICE SENSITIVE	108.02KB	Share
PTX Clinical Hold Lifted on PTX-200 Breast Cancer Trial
11/12/17	PRICE SENSITIVE	189.03KB	Share
PTX PTX to resume Clinical Trial of PTX-200 in Ovarian Cancer
06/11/17	PRICE SENSITIVE	190.6KB	Share
PTX September 2017 Appendix 4C - Quarterly
27/10/17	PRICE SENSITIVE	420.15KB	Share
PTX PTX-100 to Re-enter Trials in Hematology Niche
03/10/17	PRICE SENSITIVE	167.41KB	Share
PTX Prescient to resume AML trial
04/09/17	PRICE SENSITIVE	234.23KB	Share
PTX Appendix 4E and 2017 Annual Report
29/08/17	PRICE SENSITIVE	1.02MB	Share
PTX June 2017 Appendix 4C - Quarterly
26/07/17	PRICE SENSITIVE	426.92KB	Share
PTX Novel PTX-100 Cancer Approach Published in Nature
19/06/17	PRICE SENSITIVE	252.6KB	Share
PTX Clinical Trial Update
29/05/17	PRICE SENSITIVE	99.59KB	Share
PTX PTX Broker Presentation
16/05/17	PRICE SENSITIVE	2.62MB	Share
PTX European Patent Granted for PTX-200
12/05/17	PRICE SENSITIVE	111.75KB	Share
PTX Kansas University Joins PTX's AML Trial
08/05/17	PRICE SENSITIVE	297.41KB	Share
PTX FDA Grants Orphan Drug Designation for PTX-200 in AML
01/05/17	PRICE SENSITIVE	137.25KB	Share
PTX March 2017 Appendix 4C - Quarterly
27/04/17	PRICE SENSITIVE	139.83KB	Share
PTX Successful Completion of Phase 1b Breast Cancer Trial
06/04/17	PRICE SENSITIVE	140.85KB	Share
PTX Trading Halt
04/04/17	PRICE SENSITIVE	319.66KB	Share
PTX Response to ASX Price Query
28/03/17	PRICE SENSITIVE	574.71KB	Share
PTX Three Additional US Patents Granted
16/03/17	PRICE SENSITIVE	95.03KB	Share
PTX First Cohort Successfully Completed in Phase 1b/2 AML Trial
08/03/17	PRICE SENSITIVE	193.1KB	Share
PTX Appendix 4D and Half Year Financial Report
23/02/17	PRICE SENSITIVE	596.12KB	Share
PTX December 2016 Appendix 4C - Quarterly
25/01/17	PRICE SENSITIVE	158.04KB	Share
PTX First Patient Dosed on Phase 1b/2 AML Trial
14/12/16	PRICE SENSITIVE	111KB	Share
PTX Phase 1b/2 Ovarian Trial Commences 2nd Dose Escalation
08/12/16	PRICE SENSITIVE	408.73KB	Share
PTX Receipt of R&D Tax Rebate-PTX.AX
02/11/16	PRICE SENSITIVE	205.19KB	Share
PTX September 2016 Appendix 4C - Quarterly-PTX.AX
28/10/16	PRICE SENSITIVE	395.63KB	Share
PTX Response to ASX Price Query-PTX.AX
19/10/16	PRICE SENSITIVE	716.25KB	Share
PTX First patient at Moffitt dosed in Phase 1b/2 breast trial-PTX.AX
26/09/16	PRICE SENSITIVE	225.64KB	Share
PTX Appendix 4E and 2016 Annual Report-PTX.AX
31/08/16	PRICE SENSITIVE	800.39KB	Share
PTX USPTO Grants Allowances for Two PTX-200 Patents-PTX.AX
04/08/16	PRICE SENSITIVE	269.27KB	Share
PTX Change to exercise price of options-PTX.AX
20/07/16	PRICE SENSITIVE	218.84KB	Share
PTX June 2016 Appendix 4C - Quarterly-PTX.AX
20/07/16	PRICE SENSITIVE	197.07KB	Share
PTX Yale Joins PTX's Phase 1b/2 AML Clinical Trial-PTX.AX
15/06/16	PRICE SENSITIVE	269.24KB	Share
PTX Replacement Entitlement Offer Prospectus-PTX.AX
03/06/16	PRICE SENSITIVE	1.14MB	Share
PTX Offer Document-PTX.AX
18/05/16	PRICE SENSITIVE	4.24MB	Share
PTX PTX Secures $7.0M Capital Raising-PTX.AX
18/05/16	PRICE SENSITIVE	137.01KB	Share
PTX Trading Halt-PTX.AX
16/05/16	PRICE SENSITIVE	532KB	Share
PTX March 2016 Appendix 4C - Quarterly-PTX.AX
21/04/16	PRICE SENSITIVE	391.12KB	Share
PTX PTX-200 Breast Cancer Trial Progresses
17/02/16	PRICE SENSITIVE	128.83KB	Share
PTX Steven Yatomi-Clarke Appointed CEO
15/02/16	PRICE SENSITIVE	265.75KB	Share
PTX December 2015 Appendix 4C - Quarterly
25/01/16	PRICE SENSITIVE	467.39KB	Share
PTX Response to ASX Price Query
19/01/16	PRICE SENSITIVE	671.55KB	Share
PTX FDA Allows PTX IND for Leukemia Phase Ib & II Trials
08/01/16	PRICE SENSITIVE	332.21KB	Share
PTX Additional Placement Raises $1.0 million
25/11/15	PRICE SENSITIVE	126.81KB	Share
PTX September 2015 Appendix 4C - Quarterly
30/10/15	PRICE SENSITIVE	460.96KB	Share
PTX SPP Fully Underwritten up to target amount of $1.03 million
29/10/15	PRICE SENSITIVE	278.96KB	Share
PTX Trading Halt
28/10/15	PRICE SENSITIVE	554.76KB	Share
PTX Executive Management Change
15/10/15	PRICE SENSITIVE	108.29KB	Share
PTX Two new Patents granted to Protect Lead Asset PTX-200
31/08/15	PRICE SENSITIVE	143.62KB	Share
PTX Prescient Appendix 4E and 2015 Annual Report
28/08/15	PRICE SENSITIVE	588.32KB	Share
PTX PTX-200 Phase 1B/2 Clinical Trial Update
26/08/15	PRICE SENSITIVE	351.17KB	Share
PTX Proposed Grant of Options to Non-Executive Directors
21/08/15	PRICE SENSITIVE	124.29KB	Share
PTX June 2015 Appendix 4C - Quarterly
30/07/15	PRICE SENSITIVE	463.75KB	Share
PTX IND for Phase 1b/2 Ovarian Cancer Trial Transferred to PTX
29/06/15	PRICE SENSITIVE	126.1KB	Share
PTX US FDA Reactivates PTX's IND for PTX-100 Breast Cancer Trial
10/06/15	PRICE SENSITIVE	145.57KB	Share
PTX March 2015 Appendix 4C - Quarterly
29/04/15	PRICE SENSITIVE	434.22KB	Share
PTX Encouraging Pre-Clinical Data Presented at US Cancer Meeting
21/04/15	PRICE SENSITIVE	347.82KB	Share
PTX Approval received to transfer IND Sponsorship for PTX-200
01/04/15	PRICE SENSITIVE	68.29KB	Share
PTX Appendix 4D and Half Year Financial Report
27/02/15	PRICE SENSITIVE	1.02MB	Share
PTX Prescient Therapeutics Granted Key U.S. Patents
23/02/15	PRICE SENSITIVE	210.04KB	Share
PTX PTX Acquires Worldwide License for Cancer Biomarker p27
09/02/15	PRICE SENSITIVE	74.34KB	Share
PTX December 2014 Appendix 4C - quarterly
30/01/15	PRICE SENSITIVE	322.22KB	Share

REFRESH

First

(20min delay)
Last 4.0¢		Change 0.001(2.56%)		Mkt cap ! $32.21M

Open	High	Low	Value	Volume
4.0¢	4.1¢	3.9¢	$18.21K	455.2K

Buyers (Bids)

No.	Vol.	Price($)
2	95694	4.0¢

Sellers (Offers)

Price($)	Vol.	No.
4.1¢	622328	4

View Market Depth

No.	Vol.	Price($)
2	95694	0.040
7	949434	0.039
9	1040788	0.038
3	130515	0.037
5	429500	0.036

Price($)	Vol.	No.
0.041	622328	4
0.042	350000	2
0.043	347971	3
0.044	210000	2
0.045	407000	3

Last trade - 16.10pm 20/06/2024 (20 minute delay)


Last 4.0¢		Change 0.001 ( 0.00 %)
Open	High	Low	Volume
4.1¢	4.1¢	3.9¢	681811
Last updated 15.29pm 20/06/2024 ?

PTX (ASX) Chart

PRESCIENT THERAPEUTICS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories